Decision analytics + economic evaluation

Economic models are pivotal in assessing the financial consequences and value of new treatments. The methodologies adopted for conducting these analyses and the eventual results of such analyses are of paramount importance in receiving successful reimbursement decisions from HTA agencies.

Our decision analytics and economic evaluation team specializes in applying quantitative and qualitative methods to evaluate typical and novel scenarios that arise in pharmaceutical market access. Our approach to model development and adaptation is to work with clients to design a customized structure and interface, in accordance with submission requirements and guidelines for best practice.

We have developed different types of models to address clients’ needs, including:

• Decision-tree models
• Budget impact models (BIM)
• Cost-effectiveness analysis (CEA)
• Cost-utility analysis (CUA)
• Cost-benefit analysis (CBA)
• Cost-consequence analysis (CCA)
• Cost-minimization analysis (CMA)
• Country adaptations of global models
• Markov and semi-Markov models
• Discrete event and micro-simulation models
• Partitioned survival time models
• Early economic models
• Multiple criteria decision analysis (MCDA)
• Value of information analysis (VOI)

Our team also critically appraises models developed by other organizations and provides analytical modeling support, cost calculators, and other tools for reimbursement negotiations with payers.